Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. | Psychotherapy and psychosomatics | December 2020
Compassionate use of psychedelics
Greif, A., & Šurkala, M. | Medicine, Health Care, and Philosophy | 23 September 2020
The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats
Brandt, S. D., Walters, H. M., Partilla, J. S., Blough, B. E., Kavanagh, P. V., & Baumann, M. H. | Psychopharmacology | 01 September 2020
Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom
Nkadimeng, S. M., Nabatanzi, A., Steinmann, C. M., & Eloff, J. N. | Plants | 31 August 2020
Are Psychedelics Something New in Teaching Psychopharmacology?
Louie, A. K., Beresin, E. V., Coverdale, J., Balon, R., Guerrero, A. P., Morreale, M. K., & Brenner, A. M. | Academic Psychiatry | 28 August 2020
Plasma psilocin critically determines behavioral and neurobiological effects of psilocybin
Madsen, M. K., & Knudsen, G. M. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 25 August 2020
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., ... & Kuypers, K. P. | Journal of Psychopharmacology | 25 August 2020
P300-mediated modulations in self-other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the self-other overlap
Smigielski, L., Kometer, M., Scheidegger, M., Stress, C., Preller, K. H., Koenig, T., & Vollenweider, F. X. | Human brain mapping | 21 Aug 2020
Psychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., & O’Keane, V. | Irish journal of psychological medicine | 19 Aug 2020
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A | CNS drugs | 17 August 2020
The rise, fall, and possible rise of LSD
Snelders, S., & Pieters, T. | Tijdschrift Voor Psychiatrie | August 2020
The Current Status of Psychedelics in Psychiatry
Nutt, D., & Carhart-Harris, R. | JAMA psychiatry | 29 July 2020
Immunochemical monitoring of psilocybin and psilocin to identify hallucinogenic mushrooms
Morita, I., Oyama, H., Kiguchi, Y., Oguri, A., Fujimoto, N., Takeuchi, A., ... & Kobayashi, N. | Journal of Pharmaceutical and Biomedical Analysis | 21 July 2020
Ibogaine therapy for addiction: Consumer views from online fora
Barber, M., Gardner, J., Savic, M., & Carter, A. | Journal of Drug Policy | 18 July 2020
Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use
Roberts, C. A., Osborne-Miller, I., Cole, J., Gage, S. H., & Christiansen, P. | Journal of Psychopharmacology| 17 July 2020
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., de Araujo, D. B. | Journal of Psychopharmacology | 10 Jul 2020
Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass
Petranker, R., Anderson, T., & Farb, N. | Frontiers in psychology | 10 July 2020
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. | Chronic Stress | 8 July 2020
In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor
Pottie, E., Cannaert, A., & Stove, C. P | Archives of Toxicology | 5 July 2020
Historic psychedelic drug trials and the treatment of anxiety disorders
Weston, N. M., Gibbs, D., Bird, C. I., Daniel, A., Jelen, L. A., Knight, G., & Rucker, J. J. | Depression and Anxiety | 05 July 2020
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil
Jardim, A. V., Jardim, D. V., Chaves, B. R., Steglich, M., Ot’alora G, M., Mithoefer, M. C., Doblin, R. | Brazilian Journal of Psychiatry | 3 July 2020
The pharmacological interaction of compounds in ayahuasca: a systematic review
Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. | Brazilian Journal of Psychiatry | 03 July 2020
Synthesis and characterization of high-purity N,N-dimethyltryptamine hemifumarate for human clinical trials
Cozzi, N. V., & Daley, P. F. | Drug Testing and Analysis | 01 July 2020
Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains
Varley, T. F., Carhart-Harris, R., Roseman, L., Menon, D. K., & Stamatakis, E. A. | NeuroImage | 30 June 2020
A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression
Shiroma, P. R., Thuras, P., Wels, J., Albott, C. S., Erbes, C., Tye, S., & Lim, K. O. | Translational psychiatry | 26 June 2020